Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry
[en] Stromelysin-3 (ST3) is a matrix metalloproteinase which is expressed in fibroblastic cells of most human invasive carcinomas and represents a potential new prognostic indicator. Expression of recombinant ST3 forms in Escherichia coli from cDNA constructs indicated that high levels of expression were achieved when the ST3 pro-domain was deleted. The putative mature form of ST3 thus produced and recovered from bacterial inclusion bodies was used to prepare monoclonal antibodies (MAbs) against ST3 by immunization of BALB/C mice. Ten hybridomas producing MAbs against ST3 were obtained and analyzed for their ability to detect endogenous ST3 in breast cancer and in conditioned media from human fibroblasts. One of these MAbs (5ST-4A9) was found to be suitable for the routine detection of ST3 on breast cancer tissue sections, thus opening the possibility to evaluate ST3 prognostic value in breast cancer using semi-quantitative immunohistochemistry
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Santavicca, M.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Chenard, M. P.
Lutz, Y.
Stoll, I.
Segain, J. P.
Rouyer, N.
Rio, M. C.
Wolf, C.
Bellocq, J. P.
Basset, P.
Language :
English
Title :
Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry
Publication date :
1995
Journal title :
International Journal of Cancer
ISSN :
0020-7136
eISSN :
1097-0215
Publisher :
Wiley Liss, Inc., New York, United States - New York
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Ali S., Lutz Y., Bellocq J.P., Chenard‐neu M.P., Rouyer N., Metzger D. (1993) Production and characterization of monoclonal antibodies recognising defined regions of the human oestrogen receptor. Hybridoma 12:391-405.
Basset P., Bellocq J.P., Wolf C., Stoll I., Hutin P., Limacher J.M., Podhajcer O., Chenard M.P., Rio M.C., Chambon P. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704.
Birkedal‐hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal‐Hansen B., De Carlo A., Engler J.A. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4:7-250.
Cattoretti G., Pileri S., Parravicini C., Becker M.H.G., Poggi S., Bifulco C., Key G., D'Amato L., Sabattini E., Feudale E., Reynolds F., Gerdes J., Rilke F. (1993) Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections. J. Pathol. 171:83-98.
Chomczynski P., Sacchi N. (1987) Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal. Biochem. 162:156-159.
Docherty A.J.P., O'Connell J., Crabbe T., Angal S., Murphy G. (1992) The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 10:200-207.
Duffy M.J., Reilly D., McDermott E., O'Higgins N., Fennelly J.J., Andreasen P. (1994) Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74:2276-2280.
Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., Andreasen P. (1990) Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50:6827-6829.
Elledge R.M., McGuire W.L. (1993) Prognostic factors and therapeutic decisions in axillary node‐negative breast cancer. Ann. Rev. Med. 44:201-210.
Engel G., Heseemeyer K., Auer G., Backdahl M., Eriksson E., Linder S. (1994) Correlation between stromelysin‐3 level and outcome of human breast cancer. Int. J. Cancer 58:1-7.
Foekens J.A., Schmitt M., van Putten W.L., Peters H.A., Bontenbal M., Janicke F., Klijn J.G. (1992) Prognostic value of urokinase‐type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52:6101-6105.
Green S., Issemann I., Sheer E. (1988) A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res. 16:369.
Grondahl‐Hansen J., Christensen I.J., Rosenquist C., Brunner N., Mouridsen H.T., Dano K., Blichert‐Toft M. (1993) High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:2513-2521.
Hahnel E., Harvey J.M., Joyce R., Robbins P.D., Sterrett G.F., Hahnel R. (1993) Stromelysin‐3 expression in breast cancer biopsies: clinico‐pathological correlations. Int. J. Cancer 55:771-774.
Harris J.R., Lippman M.E., Veronesi U., Willett W. (1992) Breast cancer (1). New Engl. J. Med. 327:3-28.
Helzlsouer K.J. (1994) Epidemiology, prevention, and early detection of breast cancer. Curr. Opin. Oncol. 6:541-548.
Kawami H., Yoshida K., Ohsaki A., Kuroi K., Nishiyama M., Toge T. (1993) Stromelysin‐3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res. 13:2319-2324.
Lippman M.E. (1993) The development of biological therapies for breast cancer. Science 259:631-632.
Matrisian L.M. (1992) The matrix‐degrading metalloproteinases. Bioessays 14:455-463.
Murphy G., Segain J.P., O'Shea M., Cockett M., Ioannou C., Lefebvre O., Chambon P., Basset P. (1993) The 28‐kDa N‐terminal domain of mouse stromelysin‐3 has the general properties of a weak metalloproteinase. J. biol. Chem. 268:15435-15441.
Rouyer N., Wolf C., Chenard M.P., Rio M.C., Bellocq J.P., Chambon P., Basset P. (1994) Stromelysin‐3 gene expression in human cancer: an overview. Invasion Metastasis 14:269-275.
Stetler‐Stevenson W.G., Aznavoorian S., Liotta L.A. (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annual Review of Cell Biology 9:541-573.
Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. (1990) Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185:60-89.
Wolf C., Rouyer N., Lutz Y., Adida C., Loriot M., Belloco J.P., Chambon P., Basset P. (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc. nat. Acad. Sci. (Wash.) 90:1843-1847.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
